2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Thyroid Neoplasms
9
Hypothyroidism
7
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Sarcoma, Alveolar Soft Part
1
Recurrence
1
Postoperative Complications
1
Polycystic Ovary Syndrome
1
Neoplasms
1
Laryngeal Neoplasms
1
Infertility, Female
1
Head and Neck Neoplasms
1
Goiter
1
Fatigue
1
Depression
1
Brain Neoplasms
1
Anxiety Disorders
1
Advanced Differentiated Thyroid Gland Carcinoma
1
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
98
Fluorouracil
90
Capecitabine
86
Dexamethasone
81
Radiotherapy
80
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Leucovorin
64
Drug Therapy
64
Cetuximab
60
Erlotinib Hydrochloride
56
Sorafenib
53
atezolizumab
52
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Thyroxine
×
Clear all
NCT02548715
2022-07-13
LSHT
University of Alberta
Phase 2/3
Withdrawn